Avid Bioservices, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Avid Bioservices, Inc.
Novavax has granted Serum Institute rights to develop, manufacture and commercialize its COVID-19 vaccine candidate in a few regions. The agreement, which expands on an earlier association, gives Serum exclusive marketing rights in India till deal ends and non-exclusive rights for developing countries till pandemic lasts, with Novavax getting half of net revenue.
The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
- Contract Manufacturing Organization
- Other Names / Subsidiaries
- Techniclone Corporation Peregrine Pharmaceuticals, Inc.